12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral CUDC-101: Phase I started

Curis began a dose-escalation, U.S. Phase I trial to evaluate 200-500 mg oral CUDC-101 twice daily in 21-day cycles in about 36 patients with advanced or refractory solid tumors. Curis has...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >